Anavex Compound to be Tested in Biogen Neurological Protection Model
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- S&P 500, Nasdaq set for higher open as SK Hynix lifts chips; Fed in focus
- SK Hynix shares surge after Q3 profit beats expectations
- Oil up 1% as Saudi Arabian refinery attack reignites supply concerns
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- S&P Global explores potential separation of Capital IQ business
- Wall Street ends higher on revived AI momentum
- Nebius Group shares jump after France data center funding
- GE Vernova Inc. (GEV) Tops Q3 EPS by 81c, Beats on Revenue; Offers FY26 Revenue Guidance
- Seagate Technology (STX) Tops Q1 EPS by 29c, Offers Guidance
Biogen Agreement Further Validates Anavex Life Sciences (AVXL) AV2-73 - FBR
September 28, 2016 10:39 AM EDTFBR Capital analyst Christopher James weighed in on Anavex Life Sciences (NASDAQ: AVXL) after the company announced that it has signed a material transfer agreement with Biogen under which Biogen will test AV2-73 in a validated preclinical CNS assay. As a... More
Anavex Life Sciences (AVXL) Surges Higher; Stock Up 47%
September 28, 2016 10:12 AM EDTAnavex Life Sciences (NASDAQ: AVXL) surges to highs following this morning's testing deal with Biogen (NASDAQ: BIIB). Shares are up 46.8% on volume that is 37x normal.
... More


